Show simple item record

dc.contributor.authorvan Rhee, Fritsen_US
dc.contributor.authorRothman, Margareten_US
dc.contributor.authorHo, Kai Faien_US
dc.contributor.authorFleming, Sarahen_US
dc.contributor.authorWong, Raymond S.en_US
dc.contributor.authorFosså, Alexanderen_US
dc.contributor.authorDispenzieri, Angelaen_US
dc.contributor.authorCavet, Jamesen_US
dc.contributor.authorMunshi, Nikhilen_US
dc.contributor.authorVermeulen, Jessicaen_US
dc.contributor.authorCasper, Coreyen_US
dc.date.accessioned2015-05-04T15:27:44Z
dc.date.issued2015en_US
dc.identifier.citationvan Rhee, F., M. Rothman, K. F. Ho, S. Fleming, R. S. Wong, A. Fosså, A. Dispenzieri, et al. 2015. “Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab.” The Patient 8 (2): 207-216. doi:10.1007/s40271-015-0120-5. http://dx.doi.org/10.1007/s40271-015-0120-5.en
dc.identifier.issn1178-1653en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:15034989
dc.description.abstractBackground: Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently shown to be effective in a registration clinical trial. MCD symptoms, such as fatigue, pain, and weakness, are most appropriately quantified using patient-reported outcome (PRO) measures. We assessed the effect of siltuximab on patient perception of symptoms, functional status, and wellbeing using PRO instruments. Methods: We analyzed results of a randomized, double-blind trial comparing siltuximab 11 mg/kg every 3 weeks with placebo to treat MCD. Subjects (N = 79) completed the recently developed MCD–Symptom Scale (MCD–SS), the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) scale, and the Short Form (SF)-36 at predetermined time points throughout the treatment period. Scores were compared at baseline and over time between the treatment arms and PRO instruments. Results: At baseline, the mean number of symptoms reported was 9.2 (standard deviation 3.76) out of 16 total, as measured by the MCD–SS. Fatigue was a key symptom across all PRO instruments. Siltuximab-treated subjects reported early improvements in symptoms compared with subjects in the placebo arm on both the MCD–SS and FACIT–Fatigue scale. Statistically significant improvements in five SF-36 domains were observed in siltuximab-treated patients, namely role physical, role emotional, vitality, bodily pain, and mental health. Conclusions: Patients with MCD commonly report impairments in functioning, wellbeing, and fatigue at baseline. Siltuximab-treated patients reported significant improvements in these outcomes after treatment. Electronic supplementary material The online version of this article (doi:10.1007/s40271-015-0120-5) contains supplementary material, which is available to authorized users.en
dc.language.isoen_USen
dc.publisherSpringer International Publishingen
dc.relation.isversionofdoi:10.1007/s40271-015-0120-5en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383814/pdf/en
dash.licenseLAAen_US
dc.titlePatient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximaben
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalThe Patienten
dash.depositing.authorMunshi, Nikhilen_US
dc.date.available2015-05-04T15:27:44Z
dc.identifier.doi10.1007/s40271-015-0120-5*
dash.authorsorderedfalse
dash.contributor.affiliatedMunshi, Nikhil


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record